---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-003165"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2026-04-03T23:59:59+00:00"
generated_at: "2026-05-15T07:42:05.758641+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeOnc Q4 net loss $62.1M ($3.20/sh); NEO212 Phase 1 complete, NEO100 Phase 2a enrolled

## Summary
- Q4 net loss $62.1M ($3.20 diluted EPS) vs $11.9M ($0.69) in Q4 2024; G&A surged to $4.8M from $1.7M.
- NEO212 Phase 1 complete; RP2D set at 610 mg; company plans Type B End-of-Phase 1 FDA meeting for potential registrational study.
- NEO100 Phase 2a fully enrolled in IDH1-mutant high-grade glioma; interim data readout expected ~August 2026.
- PIPE financing anchored by $10M commitment from Cinctive Capital Management.
- Leadership additions: Amir Heshmatpour named CEO, David Choi appointed CAO; two neuro-oncologists joined SAB.

## SEC filing metadata
- accession: 0001829126-26-003165
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2026-04-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912626003165/0001829126-26-003165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912626003165/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-003165
- JSON: https://secwatch.observer/filing/0001829126-26-003165.json
- Plain text: https://secwatch.observer/filing/0001829126-26-003165.txt

## Key facts
- Earnings Releases
  NEONC TECHNOLOGIES HOLDINGS, INC. reported the quarter and year ended December 31, 2025 results: net income $62.1 million or $3.20 per diluted share, EPS $3.20 per diluted share.
  - Period: the quarter and year ended December 31, 2025
  - Net income: $62.1 million or $3.20 per diluted share
  - EPS: $3.20 per diluted share
  - Result: reported results
  source text: $3,045k in Q4 2024, driven by active management of NEO100 trial sites, recruitment for NEO212, initiation of NEO100-3, and overall patient recruitment activity. ● Net loss: $62.1 million or $3.20 per diluted share, compared to $11.9 million or $0.69 per diluted share in Q4 2024, primarily due to increased general and administrative expenses, as well as
  evidence_url: https://www.sec.gov/Archives/edgar/data/1979414/000182912626003165/0001829126-26-003165-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.